cyrilzakka/clinical-trials huggingface dataset:
Influence of Meal Skipping on Macronutrient Oxidation and Glucose Metabolism Under Isocaloric Conditions

Aim of the study is to investigate the impact of meal skipping (breakfast or dinner skipping) on the regulation of glucose metabolism and macronutrient balance (protein/fat/carbohydrate intake vs. -oxidation). An isoenergetic diet with 3 conventional meals (breakfast, lunch, dinner) serves as a control.

The duration of the study is 7 days including 3 days with controlled diet and 4 days (including 5 nights) in a metabolic chamber at the Institute of Nutritional Medicine at the University of Hohenheim.

The study phase in the metabolic chamber consists of (i) 1 day with 3 meals/day = baseline day, (ii) 1 day with breakfast skipping, (iii) 1 day with dinner skipping, (iv) 1 washout day where the subjects leave the chamber between 7 a.m. until 7 p.m..

Beginning on the 3rd study day macronutrient and energy intake as well as the fasting periods are kept constant. To achieve comparable conditions the washout day is setted before the baseline day.

Eligibility Criteria:
Inclusion Criteria:

* healthy
* not obese (BMI\<30)

Exclusion Criteria:

* food allergy
* smoking
* alternative nutrition habits
* chronic disease
* regular medication intake
* claustrophobia
The Impact of the Covid-19 Pandemic on Orthopedic Trauma Management

The aim of the study is to compare emergency orthopedic trauma admissions between the pre-pandemic period and the pandemic period and to detect changes in orthopedic trauma epidemiology.

The aim of the study is to compare emergency orthopedic trauma admissions between the pre-pandemic period and the pandemic period and to detect changes in orthopedic trauma epidemiology. For this purpose, an epidemiological study was conducted in our country, comparing trauma admissions to a level 1 trauma hospital during a one-year period before the pandemic with those in the year following the onset of the pandemic.Demographic characteristics of the patients, such as age and gender, were recorded. In addition, the injury mechanisms of the patients, diagnosis, injured extremityor anatomical region, broken bone, fracture classification, multitrauma rates, trauma releated complications, hospitalization days, and treatment modalities were examined.

Eligibility Criteria:
Inclusion Criteria:

* The patients who were admitted between March 2019 and March 2021
* Patients presenting due to trauma

Exclusion Criteria:

* Patients Admitted Before the Pandemic and Outside the Pandemic Period
* Consultation or Outpatient Clinic Patients
* Non-Traumatic Conditions
* Patients with Incomplete Records
Cross Cultural Adaptation of International Physical Activity Questionaire Short Form in Urdu Version

The IPAQ-SF scale is widely used in our clinical settings. The translated version of IPAQ-SF scale in Urdu will help the clinician in collecting data thus, easy to understand for the patient and making it more desirable in our region.

The purpose of study is to translate IPAQ-SF (International Physical Activity Questionnaire- short form) scale in Urdu and to determine the validity \& reliability of IPAQ-SF in Urdu version. Patients who are at high risk of chronic diseases such as cardiovascular disease, diabetes, and hypertension age between 30 to 65 years and can understand Urdu and English language are included in my study. 6mint walk test performed to assess aerobic capacity and endurance and physical activity over the last seven days is recorded on the translated version of IPAQ-SF in Urdu and then back of Urdu into English.

Eligibility Criteria:
Inclusion Criteria:

* Patients who have chronic diseases, such as cardiovascular, pulmonary and metabolic disease will consider as high risk, those who have more than two number of CAD risk factor will categorize as mild and patients have less than two risk factor of CAD will consider as low risk factor.(ACSM risk stratification guide lines)

Those who can read and understand English and Urdu as well.

Exclusion Criteria:

* Those with known Parkinson's disease, cerebrovascular disease or dementia.

Individuals have difficulty with reading because of low educational level
An Efficacy and Safety Study With Vandetanib to Treat Inoperable or Relapsed Malignant Mesothelioma

A clinical study to assess if a new investigational drug is effective in treating malignant mesothelioma, compared to a chemotherapy treatment (Navelbine®). In this study the patients will be assigned by chance to receive either the new drug or a chemotherapy treatment (Navelbine®). Treatment will continue as long as the cancer does not worsen and the patient wishes to continue in the study. The study will recruit approximately 66 patients.


Eligibility Criteria:
Inclusion Criteria:

* Diagnosed with mesothelioma
* Previously treated with only one course of chemotherapy for mesothelioma
* No previous treatment with vinorelbine
* No serious heart problems within the last 3 months

Exclusion Criteria:

* Serious abnormal laboratory values
* Severe or uncontrolled disease or condition as judged by the Investigator
* Pregnant or breast-feeding women
* Other cancers within the last 5 years
* Major surgery or radiation therapy within 4 weeks prior to starting study therapy
* Receipt of any investigational agents within 30 days prior to commencing study treatment.
Duration of Platelet Inhibition by Aspirin

The well established importance of regular aspirin administration stands on firm grounds, as large meta-analyses have shown this therapy to significantly reduce the risk of death. However, not all patients benefit of aspirin administration to the same extent, thus high-lighting a sub-population of patients with inadequate platelet response to ASA. The mechanisms underlying reduced ASA efficacy remain elusive. A recent report has suggested that platelets, long believed to be incapable of de novo protein synthesis, may retain their ability to form the cyclooxygenase enzyme, once it has been inactivated by aspirin. This may explain the inefficacy of the drug to induce sustained platelet inhibition in certain patients.

The current study aims to evaluate, in patients suffering from stable coronary artery disease, the stability of platelet inhibition by aspirin during the normal once daily dosing regimen.


Eligibility Criteria:
Inclusion Criteria:

* Patients suffering from stable CAD, on chronic ASA therapy
* Patients willing to participate in the study and to sign the informed consent form

Exclusion Criteria:

* Acute coronary syndrome or revascularization in the last 3 months prior to enrolment
* Concurrent ingestion of nonsteroidal anti-inflammatory drugs (NSAIDs, including COX-2 selective anti-inflammatory drugs), clopidogrel, ticlopidine, dipyridamole, warfarin or acenocoumarol
* Frequent use (more than once a week) of non-prescription NSAIDs or drugs containing ASA in the 10 days preceding enrolment
* Major surgical procedure within 1 month before enrolment
* Hemorrhagic diathesis or known platelet dysfunction
* Platelet count outside the 100 to 450 x109/L range for technical reasons
* Hematocrit \< 25% or haemoglobin \< 100 g/L
* Patient undergoing dialysis for chronic renal failure
* Patient found to be ASA resistant
Microbe-host Interaction Relationship in Patients With Stroke-relatedPneumonia

This study intends to use a standardized cohort study to collect biological samples (including throat swabs, sputum and blood) from subjects eligible for inclusion, and use 16s DNA / metagenomic sequencing and metabolome technology to explore the microbial-host interaction relationship of SAP patients.

Stroke-related pneumonia (SAP) is the most common complication of acute cerebral hemorrhage, and it is one of the main causes of disease aggravation, prolonged hospitalization and costs, and even death. The traditional antibiotic model proved ineffective, and new prevention and treatment methods were urgently sought.This study intends to use a standardized and rigorous cohort study to collect biological samples (including throat swabs, sputum and blood) of eligible subjects, and to explore the microbial-host interaction relationship in patients with SAP, which may provide new targets and new ideas for the prevention and control of SAP.

Eligibility Criteria:
Inclusion Criteria:

* Age: 18 years old;
* Stroke was confirmed by imaging;
* Within 48 hours of onset, the onset time cannot be determined from the last normal observation;
* Glasgow Coma Scale (GCS) 7-14;
* SAP by clinical symptoms, laboratory examination or imaging confirmation, the modified CDC diagnostic criteria;
* The patient (or his / her legal representative) signs a written informed consent form.

Exclusion Criteria:

* Use of antibiotics within 4 weeks before stroke onset;
* The presence of other conditions that may interfere with the follow-up and outcome assessment (such as known significant prestroke disability, mRS score of 3-5, end-stage malignancy, and liver and renal failure);
* Pregnant or lactating women.
Safety and Effectiveness of Cyclosporin in the Management of COVID19 ARDS Patients in Alexandria University Hospital

The study to evaluate the effect of cyclosporine ( IL2 inhibitor and antiviral) verse standard care treatment on decrease ADRS, hyper inflammation, hypercytokinemia, and the mortality rate

To test the efficacy of IL-2 inhibitors (Cyclosporine) compared to the Standard of care according to hospital protocol on COVID-19 patients concerning the clinical outcome (cytokines level, clinical improvement, and PCR of SARS-CoV-2 through the study period).

AIM:

The slow progression of the disease, improving survival among COVID-19 patients, and Standard assessment of patient improvement.

* Standard assessment of patient improvement:
* PCR-SARS-CoV-2 negative
* No fever
* No cytopenia (Hb ≥90 g/L, ANC ≥0.5x109/L, platelets ≥100x109/L) •
* No hyperferritinemia ≥500 μg/L
* (Decrease of IL2)

Eligibility Criteria:
Inclusion Criteria:

1. Current infection with COVID-19
2. written informed consent
3. Confirmed diagnosis of COVID-19 by PCR (polymerase chain reaction) tests and/or Positive Serology or any existing and validated diagnostic COVID-19 parameters during this time.
4. 18yrs ≥ Age \<66 yrs
5. Chest X-ray showing suggestive of COVID-19 disease.
6. Both gender
7. The presence of Pulmonary fibrosis or hyper inflammation signs or A syndrome of cytokine release defined as any of the following::

   1. Leukopenia or lymphopenia,
   2. Ferritin \> 500ng/mL or D-dimers ≥ 500 ng/mL
   3. Hs\>90

Exclusion Criteria:

1. Lactation and Pregnancy women
2. unlikely to survive beyond 48h
3. Need for mechanical ventilation.
4. cases of multiorgan failure or abnormal renal function and shock.
5. malignancies, autoimmune disease, Perforation of the bowels or diverticulitis.
6. active bacterial or fungal infection.
7. We define impairment of cardiac function as poorly controlled heart diseases, cardiac insufficiency, unstable angina pectoris, myocardial infarction within 1 year before enrollment, supraventricular or ventricular arrhythmia needs treatment or intervention, Uncontrolled hypertension (\>180/110 mmHg.
8. Levels of serum transaminase \>5 upper references rang
9. Symptoms of active tuberculosis or human immunodeficiency virus (HIV) positivity
10. the patient receiving Vaccines: Live, attenuated vaccines
11. Subjects received monoclonal antibodies within one week before admission.
12. Patients receiving high-dose systemic steroids (\> 20 mg methylprednisolone or equivalent), immunosuppressant or immunomodulatory drugs
13. Contraindications for use in people with psoriasis include concomitant treatment with methotrexate, other immunosuppressant agents, coal tar, or radiation therapy.

    -
A Comparison of Recombinant Human Brain Natriuretic Peptide and Dobutamine

To compare the therapeutic efficacy of recombinant human brain natriuretic peptide (rhBNP) with dobutamine on acute decompensated heart failure patients with different blood BNP levels

Patients with acute decompensated heart failure (ADHF) whose left ventricular ejection fraction(LVEF) was \<40%, were assigned to a high BNP group (BNP ≤ 3000 pg/mL) or an extra-high BNP group (BNP \> 3000 pg/mL) , depending on their admission plasma BNP levels. Each group was then subdivided into rhBNP or dobutamine subgroups according to intravenous administration with either rhBNP or dobutamine for 24-72h. The effects of rhBNP and dobutamine on patients in the high and extra-high BNP groups were compared.

Eligibility Criteria:
Inclusion Criteria:

* patients were classified as NYHA class III-IV
* ejection fraction \<40%

Exclusion Criteria:

* intravenous administration with rhBNP or dobutamine in the 2 weeks before study entry
* acute myocardial infarction
* significant valvular stenosis
* serious ventricular arrhythmia (frequent ventricular premature beat of \>5 bpm, nonsustained and sustained ventricular tachycardia)
* blood pressure \<95/60 mmHg or \>140/90 mmHg
* shock
* hypovolemia
* hepatic or renal impairment
* pregnant and lactating women.
Analysis of Bone Microarchitecture With HR-pQCT of Patients With Chronic Kidney Disease (CKD) Candidates for Renal Transplantation

While the duration of renal transplant function has increased over the last decade kidney transplanted patients (KTP) still exhibit a fracture risk 4 times higher than in the general population. Fracture risk remains increased despite the improvement of immunosuppressive therapies (IST) that allowed the reduction of steroid administration. Potential explanations for this could be 1) that Chronic Kidney Disease (CKD) induces renal osteodystrophy that occurs before kidney transplanted, impairs bone metabolism and promotes bone fragility ; 2) that kidney transplanted patients are older and older (14% of kidney transplanted patients were older than 70 in 2011 in France), ageing being a major risk factor for fractures 3) IST, besides steroid, may have deleterious effects on bone and 4) that secondary hyperparathyroidism, a risk factor of fractures, persists after kidney transplanted . Thus, the pathophysiology and epidemiology of bone fragility of kidney transplanted patient remains insufficiently characterized. Despite these data, and contrarily to what is done for patients candidates for cardiac transplantation, there is no general consensus for performing bone evaluation before kidney transplanted . Thus it's necessary to individualize the management of bone fragility and prevent fractures according to strategies that remain to be defined, provided that patients at risk are better detected.

Bone fragility is determined by quantitative parameters (bone mass) and qualitative parameters including macro- and micro-architecture (especially cortical porosity and thickness). The Dual Energy X-ray Absorptiometry (DEXA ) measurement of Bone Mineral Density (BMD) is a robust predictor of fracture risk in the non-uremic population. Micro and macro-architecture can be measured with High Resolution peripheral micro Computerized Tomography (HRpQCT) at the ankle and the wrist . Some recent studies suggested that HRpQCT could be a better fracture predictor than DEXA in uremic populations. In this context, the aim of our project is to describe in a cross sectional study the bone status of CKD patients, candidates for kidney transplanted . It will be 1) calculated the prevalence of cortical osteoporosis as assessed by cortical thickness at the ankle and the wrist (primary end point), 2) analyzed other HRpQCT microarchitecture quantitative parameters and 3) defined the biological and clinical factors associated with bone degradation (secondary endpoints). This population will be compared to age and sex matched normal subjects (collaboration with Pr Rizzoli, Geneva, Switzerland). The DEXA and HRpQCT will be compared for detection of patients at risk for fracture.

Eligibility Criteria:
Inclusion Criteria:

* Serum parathyroidal Hormon (PTH ) \> 65pg/ml
* Stage 5 or 5D Chronic Kidney Disease patients
* Patient registered (or on the verge of being registered) on the KT waiting list at St-Etienne Hospital, France
* Written consent of patient

Exclusion Criteria:

* none
MIYOPERİCYTOMA OF ORAL MUCOSE: CASE REPORT

Miyopericytoma (MPC) is defined as a benign tumor consisting mostly of oval-spindle-shaped myoid-appearing cells with perivascular growth. It may involve a single or multiple anatomical regions and may be multifocal and tends to occur mainly in the extremities, dermal and superficial soft tissues of adults. Cases of miyopericytoma due to trauma have been reported.Histological features and clinical course are generally benign, but features suggestive of low-grade malignancy were seen in MPCs. Myopericytoma in the oral and maxillofacial region is rare and a limited number of cases have been reported in the literature.

A 42-year-old female patient was admitted to our clinic with an enlarging lesion on the lingual aspect of the anterior mandible, which she noticed 2 years ago. As a result of the examination, a smooth-surfaced, off-white, pedunculated, fibrotic, painless, and non-bleeding lesion was detected in the lingual aspect of the anterior mandible. The lesion was removed by excisional biopsy.


Eligibility Criteria:
Inclusion Criteria:

Patient with a fibrotic lesion in the mouth

Exclusion Criteria:

Patient without fibrotic lesions in the mouth.
Buspirone Treatment for Marijuana Dependence

Marijuana is the most commonly used illicit drug, yet few clinical trials have evaluated pharmacotherapy treatments for marijuana dependence. This study will evaluate the efficacy of buspirone for reducing marijuana use in marijuana-dependent adults. A contingency management (CM) intervention and motivational enhancement therapy (MET) will be incorporated to encourage study engagement and retention. It is hypothesized that buspirone combined with MET and CM will reduce the percent of marijuana-positive urine drug screen results in marijuana-dependent individuals as compared to a placebo treatment combined with MET and CM.


Eligibility Criteria:
Inclusion Criteria:

* Must meet DSM-IV criteria for marijuana dependence.
* Must be between the ages of 18 and 65 years.
* If female and of childbearing potential, must agree to use acceptable methods of birth control for the duration of the trial.
* Must consent to random assignment, and be willing to commit to psychosocial behavioral and medication treatment.
* Must be able to read and provide informed consent.

Exclusion Criteria:

* Women who are pregnant, nursing, or plan to become pregnant during the course of the study.
* Must not have a history of or current psychotic disorder, bipolar disorder, or eating disorder.
* Must not pose a current suicidal or homicidal risk.
* Must not meet current criteria for major depression.
* Must not have evidence or history of serious hematologic, endocrine, cardiovascular, pulmonary, renal, gastrointestinal or neurologic disease.
* Must not require concomitant therapy with psychotropic medication.
* Must not be currently dependent on other substances, with the exception of nicotine or caffeine.
* Hypersensitivity to buspirone or any other product component.
* Patients who, in the investigator's opinion, would be unable to comply with study procedures or assessments, or would be unacceptable study candidates (e.g., poses threat to staff).
Study of the Prevalence of Iron Deficiency in Patients With Chronic Inflammatory Bowel Disease

Despite its known prevalence in IBD, a recent study conducted with Prof. Cacoub (unpublished) on the national health insurance database showed that iron deficiency was an under-diagnosed and under-treated co-morbidity. In chronic diseases including IBD, Transferrin Saturation Factor is only performed in approximately 10% of cases, whereas it is recommended in inflammatory situations including IBD patients (HAS 2011).

The objective of this study is therefore to obtain updated French data on the prevalence of iron deficiency in patients with IBD by applying the recommendations of ECCO and French Health High Authority (determination of ferritinemia and Transferrin Saturation Factor)


Eligibility Criteria:
Inclusion Criteria:

* Patient, male or female, over 18 years old
* Patient present at the hospital on the day of the study
* Diagnosis of IBD on international criteria
* Patient giving written consent

Exclusion Criteria:

* Protected patient: major under guardianship, curatorship or other legal protection, deprived of liberty by judicial or administrative decision;
* pregnant, lactating or parturient woman;
* Patient hospitalized without consent
Efficacy and Safety of AEB071 Versus Tacrolimus in Combination With Mycophenolate Acid Sodium, Basiliximab and Steroids in Preventing Acute Rejection After Kidney Transplantation

Efficacy and safety of AEB071 in combination with mycophenolate acid sodium, basiliximab and steroids in preventing acute rejection after kidney transplantation.


Eligibility Criteria:
Inclusion:

* Male and female patients of any race 18 years or older
* Adult recipients of kidney transplant from a deceased or living donor
* Recipients of a functioning kidney within 24 hours post transplant

Exclusion:

* Need for medication prohibited by the protocol
* Patients or donors infected with Hepatitis B,C or HIV
* Patients with a history of cancer within last 5 years
* Patients with history of significant cardiac disorder
* Patients of high-risk immunological status

Other protocol-defined inclusion/exclusion criteria may apply.
Efficiency of the Super Inductive System in Spasticity Treatment

The aim of the study is to see whether a physical therapy program can relieve pain, decrease spasticity and increase muscle contraction force by using the super inductive system (high frequency electromagnetic field). It is a longitudinal, prospective study, of 60 patients with spasticity after stroke. No new treatment method is tested, as the Super inductive system is approved for physical therapy by the Ministry of Health.

The 60 patients will be submitted to 2 treatment groups: 30 patients will receive 10 sessions of the superinductive system on the antagonist muscles, and 30 patients will receive 10 sessions the superinductive system on the agonist and antagonist muscles. All patients will also receive the standard kinetotherapy program for spasticity. The patients will be evaluated at the beginning of the treatment, at 10 days and at 30 days by using the functional MAS index and Barthel index.

Eligibility Criteria:
Inclusion Criteria:

* spasticity after stroke

Exclusion Criteria:

* spasticity of other causes
Glucose in Dialysis Water in Diabetics With Chronic Renal Failure

The purposes are 1. to measure the effect of dialysis with glucose in dialysis water on blood pressure, pulse rate, plasma concentration of glucose, plasma concentrations og insulin, glucagon, growth hormone, renin, angiotensin II, endothelin and body temperature, and 2. to analyse the relationship between the changes in blood pressure and changes in vasoactive hormones

The relationship between blood pressure during dialysis treatment and vasoactive hormones are studied. This includes measurements of plasma concentration of glucose, plasma concentrations og insulin, glucagon, growth hormone, renin, angiotensin II, endothelin

Eligibility Criteria:
Inclusion Criteria:

1. Age \> 18 years,
2. Both men and women,
3. Dialysis treatment for at least three month due to diabetic nephropathy

Exclusion Criteria:

1. Heart failure,
2. Lung insufficiency,
3. Chronic liver disease,
4. Malignant disease,
5. Nephrotic syndrome,
6. Lack of compliance,
7. Unwillingness to participate